Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Endo Pharma sues Mylan on migraine drug
The case was filed in connection with the submission of abbreviated new drug application (ANDA) for Frovatriptan Succinate EQ, 2.5mg base tablets with the US Food and Drug
The case was filed in connection with the submission of abbreviated new drug application (ANDA) for Frovatriptan Succinate EQ, 2.5mg base tablets with the US Food and Drug
COTI-2 uses the company’s proprietary artificial intelligence system – Chemsas which uses a series of predictive computer models to identify compounds integrated in disease-specific drug discovery. COTI-2 inhibits
The trial, which treated 12 patients in The Netherlands, evaluated RPL554 for a period of 6 days with daily doses in patients with mild asthma. The trial results
The company’s loss from operations for the second quarter of 2011 was $364,000, compared to $1.97m for the same period in 2010. For the six months ended 30
The deal covers Yemen, Syria, Tunisia, Sudan, Morocco, South Sudan, Jordan, Lebanon Libya, Algeria, Iraq and Egypt. Further details of the agreement were not disclosed. Hikma Pharma CEO
The study is intended to evaluate CUDC-101 when administered concurrently with radiation and cisplatin in human papillomavirus negative (HPV-) locally advanced head and neck cancer patients. The company
Egrifta, a once-daily injection, is a novel, stabilized analogue of GRF. GRF is a hypothalamic peptide that acts on the pituitary cells in the brain to stimulate the
PAA Laboratories is a developer and manufacturer of specialized and cell culture products such as media, sera, growth supplements and reagents for use in biomedical research and in
The colon-screen will use Phloral coating technology to deliver the drug to the target site by applying two mechanisms to trigger drug release. The mechanism is based on
Eylea is indicated as a treatment for neovascular age-related macular degeneration (wet AMD). The extension of three months follows the recent amendment made by the company on the